ArticleDiagnostic pathology2014
Study of β-catenin, E-cadherin and vimentin in oral squamous cell carcinoma with and without lymph node metastases.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Association of Epithelial to Mesenchymal transition Markers on Prognosis and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Head and neck pathology · 2025Pooled it
- Clinicopathological Significance of Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Molecular mechanisms of therapeutic resistance in areca nut-associated oral squamous cell carcinoma: the interplay of chronic inflammation and epithelial-mesenchymal transition.Frontiers in oncology · 2026Review
- The Inflammatory-Dysplastic Spectrum in Oral Lichen Planus: A Study on Six Immunohistochemical Markers.Diagnostics (Basel, Switzerland) · 2025Article
- Prognostic impact of the loss of E-cadherin andFrontiers in oncology · 2023Article
- Role of Vimentin and E-cadherin Expression in Premalignant and Malignant Lesions of Oral Cavity.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Article
- Biomarker Potential of Vimentin in Oral Cancers.Life (Basel, Switzerland) · 2022Review
- Review
- Involvement of RUVBL1 in WNT/Disease markers · 2022Article
- Immunohistochemical Expression of the Epithelial to Mesenchymal Transition Proteins E-cadherin and ß-catenin in Grades of Oral Squamous Cell Carcinoma.Journal of pharmacy & bioallied sciences · 2021Article
- Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance.Signal transduction and targeted therapy · 2020Article
- Alternation of β-catenin and CD44s Immunoexpression in Different Histopathological Grades of Oral Squamous Cell Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Role and mechanism of PTEN in Burkitt's lymphoma.Oncology reports · 2020Article
- Impact of Histological and Molecular Parameters on Prognosis of Oral Squamous Cell Carcinoma: Analysis of 290 Cases.BioMed research international · 2020Article
- WISP-1 Promotes Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells Via the miR-153-3p/Snail Axis.Cancers · 2019Article
- Vimentin and Non-Muscle Myosin IIA are Members of the Neural Precursor Cell Expressed Developmentally Down-Regulated 9 (NEDD9) Interactome in Head and Neck Squamous Cell Carcinoma Cells.Translational oncology · 2019Article
- Role of E-cadherin and cyclin D1 as predictive markers of aggression and clonal expansion in head and neck squamous cell carcinoma.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2018Article
- Differences in E-Cadherin and Syndecan-1 Expression in Different Types of Ameloblastomas.Analytical cellular pathology (Amsterdam) · 2018Article
- Prognostic Prediction of Oral Squamous Cell Carcinoma by E-Cadherin and N-Cadherin Expression in Overall Cells in Tumor Nests or Tumor Cells at the Invasive Front.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite great improvement in the surgical treatment and adjunctive therapy for oral squamous cell carcinoma (OSCC), prognosis remains dismal in advanced cases. Regional metastatic disease is known to reduce recurrence free survival and disease specific survival significantly. The present study was conducted to evaluate the role of cell adhesion molecules β-catenin, E-cadherin and vimentin in predicting tumour metastasis of OSCC.
methodsA total of sixty cases of oral squamous cell carcinoma were included for the study which comprised of 30 cases with lymph node metastases and 30 cases without metastases. Immunohistochemistry was performed for β-catenin, E-cadherin and vimentin on both the test groups along with 30 controls from normal buccal mucosa and inflammatory lesions each.
resultsThere was no significant difference between the immunoreactivity for β-catenin, E-cadherin and vimentin between OSCC with and without lymph node metastases. Vimentin immunopositivity was noted with varying intensity in all cases of OSCC.
conclusionsE-cadherin and β-catenin are probably not the key determinants for regional metastases in OSCC. The role of vimentin expression in OSCC and metastases is controversial and needs to be studied further. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6506095201182002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.